Inclusion Criteria:

Diagnosis of EBV-positive Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL; all histological subtypes except Burkitt's lymphoma), or EBV (associated)-T/NK-LPD, or chronic active EBV infection (CAEBV) after second or subsequent relapse including after autologous or syngeneic stem cell transplant (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated). CAEBV is defined as i) illness for greater than 3 months duration (EBV-related illness or symptoms including fever, persistent hepatitis, extensive lymphadenopathy, or hepatosplenomegaly); ii) increased amounts of EBV-DNA in peripheral blood (equal or greater than 400 genome copies per ug of DNA) or abnormal high levels of EBV antibodies (VCA IgG equal or greater than 1:5120 or EA IgG equal or greater than 1:640; and iii) no evidence of previous immunological abnormalities or other recent infection that might explain the observed condition.

Patients with life expectancy greater than 6 weeks.

Patients with a Karnofsky score (age ≥16) of greater than 50 or Lansky score (age<16) of greater than 50

No severe intercurrent infection.

HIV negative donor (if autologous donor, patient must be HIV negative)

Patient, parent/guardian able to give informed consent.

Patients with bilirubin less than3 x normal, AST less than 5 x normal, and Hgb greater than 8.0

Patients with a creatinine less than 2 x normal for age

Patients should have been off other investigational therapy including T cell therapies for one month prior to entry in this study.

Female patients with reproductive capacity must have a negative pregnancy test. Women of childbearing potential must not be pregnant and must be on effective birth control. The male partner should use a condom.

Note: Patients who would be excluded from the protocol strictly for laboratory abnormalities can be included at the investigator¡¦s discretion after approval by the CAGT Protocol Review Committee and the FDA reviewer.

Exclusion Criteria:

• Patient, parent/guardian unable or unwilling to give informed consent
• Pregnant women
• Patients with a Karnofsky score of < 50
• Patients with a severe intercurrent infection
• Patients with a life expectancy of <6 weeks
• Patients with a bilirubin greater than 3x normal. AST greater than 5x normal and Hgb less than 8.0 g/dl
• Patients with a creatinine greater than 2x normal for age
• Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom.

Note: Patients who would be excluded from the protocol strictly for laboratory abnormalities can be included at the investigator's discretion after approval by the CCGT Protocol Review Committee and the FDA reviewer.